Opioid switching to improve pain relief and drug tolerability

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Quigley, Columba ^a   Vora, Rohan R ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b GOLD COAST HOSPITAL AND HEALTH SERVICE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; CHRONIC DISEASE; COMPLICATION; DRUG SUBSTITUTION; HUMAN; NEOPLASM; PAIN;

MORPHINE; NARCOTIC ANALGESIC AGENT;

ANALGESICS, OPIOID; CHRONIC DISEASE; DRUG SUBSTITUTION; HUMANS; MORPHINE; NEOPLASMS; PAIN;

EID: 84899466944     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004847.pub2     Document Type: Review

References (73)

1. Bruera E, Miller L, McCallion J, et al.Cognitive failure in patients with terminal cancer: a prospective study. Journal of Pain and Symptom Management 1992;7:192-5.
2. Eisele JH, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992;49:231-2.
3. Graham PH. Opioid substitution to reduce adverse effects in cancer pain management. Medical Journal of Australia 1999;170:454-5.
4. Hunt R, Fazekas B, Thorne D, et al.A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. Journal of Pain and Symptom Management 1999;18:111-9.
5. Kaiko RF, Foley KM, Grabinski PY, et al.Central nervous system excitatory effects of meperidine in cancer patients. Annals of Neurology 1983;13:180-5.
6. McDonald P, Graham P, Clayton M, et al.Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliative Medicine 1991;5:323-9.
7. Mercadante S, Sapio M, Serretta R, et al.Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. Annals of Oncology 1996;7:613-7.
8. Murray P. Substitution of another opioid for morphine may be useful for pain control. BMJ 1998;316(7132):702-3.
9. Radbruch L, Sabatowski R, Loick G, et al.Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliative Medicine 2000;14:111-9.
10. Ripamonti C, Groff L, Brunelli C, et al.Switching from morphine to oral methadone: what is the equianalgesic dose ratio?. Journal of Clinical Oncology 1998;16:3216-21.
11. Sjogren P, Dragsted L, Christensen CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesth Scan 1993;37:780-2.
12. Waller SL, Bailey M. Hallucinations during morphine administration. Lancet 1987;2(8562):801.
13. Wong JO, Chiu GL, Tsao CJ, et al.Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997;35:25-32.
14. Wood MM, Ashby MA, Somogyi AA, et al.Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. Journal of Pain and Symptom Management 1998;16:112-20.
15. Allan L, Hays H, Jensen NHJ, et al.Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8.
16. Ashby MA, Martin P, Jackson KA. Opioid substitution to reduce adverse effects in cancer pain management. Medical Journal of Australia 1999;170:68-71.
17. Bruera E, Schoeller T, Montejo G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992;48:397-9.
18. Bruera E, Watanabe S, Fainsinger RL, et al.Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995;62:141-6.
19. Bruera E, Franco JJ, Maltoni M, et al.Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. Journal of Pain and Symptom Management 1995;10:287-91.
20. Bruera E, Pereira J, Watanabe S, et al.Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996;78:852-7.
21. Cherny NJ, Chang V, Frager G, et al.Opioid pharmacotherapy in the management of cancer pain. Cancer 1995;76:1288-93.
22. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al.Strategies to manage the adverse effects of oral morphine: an evidence-based report. Journal of Clinical Oncology 2001;19:2542-54.
23. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Cancer 1993;72:2266-72.
24. Daeninck PJ, Bruera E. Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases. Journal of Pain and Symptom Management 1999;18:303-9.
25. Daeninck PJ, Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity?. Acta Anaesthesiol Scand 1999;43:924-38.
26. De Conno F, Groff L, Brunelli C, et al.Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. Journal of Clinical Oncology 1996;14:2836-42.
27. de Leon-Casasola OA, Lema MJ. Epidural bupivicaine/sufentanil therapy for postoperative pain control in patients tolerant to opioid and unresponsive to epidural bupivicaine/morphine. Anesthesiology 1994;80:303-9.
28. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. Journal of Pain and Symptom Management 1995;10:378-84.
29. del Rosario MAB, Feria M, Martin AS. Reversible delirium during opioid switching from transdermal fentanyl to methadone. Journal of Pain and Symptom Management 2001;21:177-8.
30. Fainsinger RL, Bruera E. Is this opioid analgesic tolerance?. Journal of Pain and Symptom Management 1995;10(7):573-7.
31. Fitzgibbon DR, Ready LB. Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997;73:259-61.
32. Foley K. The treatment of cancer pain. New England Journal of Medicine 1985;313:84-95.
33. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. Journal of Pain and Symptom Management 1999;18:120-5.
34. Gagnon B, Bielech M, Watanabe S, et al.The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Supportive Care Cancer 1999;7:265-70.
35. Galer BS, Coyle N, Pasternak GW, et al.Individual variability in the response to different opioids: report of five cases. Pain 1992;49:87-91.
36. Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. Journal of Pain and Symptom Management 1997;14:51-8.
37. Jacox A, Carr DB, Payne R. Management of cancer pain. Clinical Practice Guideline No. 9 (AHCPR Publication no. 94-0592). Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.
38. Jadad AR, Moore RA, Carroll D, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clinical Trials 1996;17:1-12.
39. Jellema JG. Hallucination during sustained-release morphine and methadone. Lancet 1987;ii:392.
40. Kalso E, Vainio A. Hallucinations during morphine but not oxycodone treatment. Lancet 1988;56:912.
41. Katcher J, Walsh D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. Journal of Pain and Symptom Management 1999;17:70-2.
42. Kloke M, Rapp M, Bosse B, Kloke O. Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer 2000;8:479-86.
43. Lawlor P, Walker P, Bruera E, Mitchell S. Severe opioid toxicity and somatization of psychosocial distress in a cancer patient with a background of chemical dependence. Journal of Pain and Symptom Management 1997;13:356-61.
44. Lawlor PG, Turner KS, Hanson J, et al.Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Pain 1997;72:79-85.
45. Lawlor P, Turner K, Hanson J, et al.Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998;82:1167-73.
46. Lee MA, Leng MEF, Tiernan EJJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliative Medicine 2001;15:26-34.
47. Leng G, Finnegan MJ. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliative Medicine 1994;8:153-5.
48. Loitman JE. Transmucosal fentanyl in ovarian cancer. Journal of Pain and Symptom Management 2002;23:5-6.
49. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993;53:353-5.
50. Maddocks I, Somogyi A, Abbott F, et al.Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. Journal of Pain and Symptom Management 1996;12:182-9.
51. Manfredi PL, Borsook D, Chandler SW, et al.Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997;70:99-101.
52. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of Clinical Oncology 1999;17:3307-12.
53. Mercadante S, Casuccio A, Fulfaro F, et al.Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. Journal of Clinical Oncology 2001;19:2898-904.
54. Morley JS, Watt JWG, Wells JC, et al.Methadone in pain uncontrolled by morphine. Lancet 1993;342:1243.
55. Moryl N, Santiago-Palma J, Kornick C, et al.Pitfalls of opioid rotation:substituting another opioid for methadone in patients with cancer pain. Pain 2002;96:325-8.
56. Paix A, Coleman A, Lees J, et al.Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995;63:263-9.
57. Parkinson SK, Bailey SL, Little WL, Mueller JB. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990;72:743-5.
58. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesthesia and Analgesia 2000;90:933-7.
59. Rimmer T, Trotman I. Methadone restores opioid sensitivity in cancer pain (abstract). Palliative Medicine 1996;10:58.
60. Ripamonti C, De Conno F, Groff L, et al.Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Annals of Oncology 1998;9:79-83.
61. Sabatowski R, Kasper SM, Radbruch L. Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine. Journal of Pain and Symptom Management 2002;23:3-5.
62. Santiago-Palma J, Khojainova N, Kornick C, et al.Intravenous methadone in the management of chronic cancer pain. Cancer 2001;92:1919-25.
63. Sawe J, Hansen J, Ginman C, et al.Patient-controlled dose regimen of methadone for chronic cancer pain. BMJ 1981;282:771-3.
64. Shaiova L, Sperber KT, Hord ED. Methadone for refractory cancer pain. Journal of Pain and Symptom Management 2002;23:178-9.
65. Sjogren P, Jensen N, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994;59:313-6.
66. Slover R. Transdermal Fentanyl: Clinical Trial at the University of Colorado Health Sciences Center. Journal of Pain and Symptom Management 1992;7(3S):S45-47.
67. Steinberg RB, Gilman DE, Johnson III F. Acute toxic delirium in a patient using transdermal fentanyl. Anesthesia and Analgesia 1992;75:1014-6.
68. Thomas Z, Bruera E. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. Journal of Pain and Symptom Management 1995;10:315-7.
69. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. Acta Anaesthesiol Scand 1999;43:918-23.
70. Tse DMW, Sham MKM, Ng DKH, Ma HM. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliative Medicine 2003;17:206-11.
71. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996;67:115-9.
72. Walsh D, Mahmoud FA, Sarhill N, et al.Parenteral opioid rotation in advanced cancer: a prospective study. Proceedings of ASCO. 2002; Vol. 21:Abstract 1429.
73. World Health Organization. Cancer Pain Relief. 2nd Edition. Geneva: World Health Organization, 1996.